China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement
China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...
Policy / Regulatory
NMPA Updates Rules on Domestic Production of Imported Medical Devices
The National Medical Products Administration (NMPA) has released a notification on further adjusting and optimizing...
Driving Innovation in Traditional Chinese Medicine: A Policy-Backed Renaissance
In Depth Analysis of Policy News in the Pharmaceutical Sector: A Comprehensive Guide to the...
CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...
NMPA Seeks Public Input on Drug Trial Data Protection Measures
On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...
CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings
The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...
HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process
HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th...
China Issues Guidelines for Informatization of Compact County-level Medical Communities
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...
China’s NHSA Issues Guidelines for Neurological Medical Services Pricing
China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation...
Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown
In a momentous address at the Third Session of the 14th National People’s Congress on...
CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D
China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...
National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...
AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments
The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...
In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications
The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...
State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms
The State Council has released a second draft proposal outlining measures to support the high-quality...
Shanghai Issues Legal Guidebook for Innovative Drug Marketing
The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...
China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation
The Chinese government has released a set of opinions detailing the establishment of a new...
Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025
In a significant move to bolster foreign investment and enhance the country’s economic openness, the...
New Guidelines for Advanced Gastric Cancer Drug Development Released in China
The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...